Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies

M R Turner1, S R Irani, M I Leite

  • 1Oxford University Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, UK.

Neurology
|July 22, 2011
PubMed
Abstract

Insights

This study details a rare, rapidly fatal case of autoimmune encephalomyelitis, presenting with features of progressive encephalomyelitis with rigidity and myoclonus (PERM). The patient had antibodies against both NMDA receptors and glycine receptors, leading to a severe clinical course.

Area of Science:

  • Neuroimmunology
  • Neuropathology

Background:

  • Progressive encephalomyelitis with rigidity and myoclonus (PERM) is a rare neurological disorder.
  • Historically, PERM has been associated with glycine receptor (GlyR) antibodies.

Observation:

  • A previously healthy 28-year-old man presented with a rapidly progressing, fatal form of PERM over two months.
  • Postmortem analysis revealed autoimmune encephalomyelitis with specific neuronal cell involvement.

Findings:

  • Serum antibodies against both NMDA receptors (NMDAR) and glycine receptors (GlyR) were detected.
  • Brain examination showed autoimmune inflammation targeting hippocampal pyramidal and cerebellar Purkinje cells, with relative neocortical sparing.
  • No underlying malignancy was identified.

Implications:

  • This case highlights an unusual co-occurrence of NMDAR and GlyR antibodies in PERM.
  • The combined antibody profile may explain the particularly aggressive disease progression and sudden death observed.
  • This finding expands the understanding of autoimmune encephalitis phenotypes and their associated antibody targets.

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...